ProPhase Labs to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 30, 2022 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, March 24, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified company offering a range of services including diagnostic testing, genomics testing and contract manufacturing, will hold a conference call on Wednesday, March 30, 2022 at 11:00 a.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period.

To access the call, please use the following information:

Participants can register for the conference call by navigating to:

https://dpregister.com/sreg/10164499/f1e84ec36b

Please note that registered participants will receive their dial in number upon registration. Pre-registration required fields of information include: name, phone, company, email.

Those without internet access or unable to pre-register may dial in to the conference call by calling:

Please call the conference telephone number 5-10 minutes prior to the start time and ask to be joined into the ProPhase Labs, Inc. conference call. An operator will register your name, phone and organization.

The conference call will be broadcast live and available for replay at https://services.choruscall.com/mediaframe/webcast.html?webcastid=XR6Twsmq and via the investor relations section of the Company's website at www.ProPhaseLabs.com.

A replay of the conference call will be available two hours from when the call ends.

About ProPhase Labs

ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified company that offers a range of services, including diagnostic testing, genomics testing and contract manufacturing.

ProPhase Diagnostics, Inc., a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

ProPhase Precision Medicine, Inc., a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

ProPhase Global Healthcare, Inc., a subsidiary of ProPhase, was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements^® brand.

ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.

For more information, visit www.ProPhaseLabs.com.

Investor Contact: 
ProPhase Labs, Inc.
267-880-1111

Released March 24, 2022